Company Focus
Alnylam Pharmaceuticals
Latest Alnylam Pharmaceuticals News
Pharmaceutical
The biopharma industry showed signs of recovery in the third quarter (Q3) of 2024, with increased investor optimism following the interest rate cuts by the US Federal Reserve in September 2024, according to GlobalData. 29 October 2024
Related News
Insights
Company Spotlight
A biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology.
Latest News & Features of interest to Alnylam Pharmaceuticals
Biotechnology
US biopharma Neurocrine Biosciences closed Wednesday’s trading 19% lower, at $123.76. 29 August 2024
Pharmaceutical
Flagship Pioneering yesterday demonstrated further acceleration in its strategic partnership with Pfizer, announcing two research programs with Flagship-founded Quotient Therapeutics. 29 August 2024
Biotechnology
Novartis today announced positive top-line results from twice-yearly Leqvio (inclisiran) in the Phase III V-MONO study, which met its primary endpoints. 28 August 2024
Biotechnology
US gene therapy biotech Tern Therapeutics has announced its launch and closing of a $15 million financing. 28 August 2024
Pharmaceutical
US pharma giant Merck & Co has announced that the European Commission (EC) has approved Winrevair (sotatercept), in combination with other pulmonary arterial hypertension (PAH) therapies, for the treatment of PAH in adult patients with World Health Organization (WHO) functional class (FC) II to III, to improve exercise capacity. 27 August 2024
Pharmaceutical
Swiss biopharma Addex Therapeutics and US specialty pharma Indivior have announced the selection of clinical candidates from their gamma-aminobutyric acid subtype B (GABAB) positive allosteric modulator (PAM) research collaboration. 27 August 2024
Biotechnology
The US Food and Drug Administration on Monday revised the Emergency Use Authorization (EUA) for Invivyd’s Pemgarda (pemivibart) to limit its use to when the combined national frequency of variants with substantially reduced susceptibility to Pemgarda is less than or equal to 90%. 27 August 2024
Pharmaceutical
Italian ophthalmics company SIFI SpA says that the European Commission has approved Akantior (polihexanide) for the treatment of acanthamoeba keratitis (AK) 27 August 2024
Pharmaceutical
Ireland-headquartered Jazz Pharmaceuticals last week announced disappointing top-line results from the Phase III open-label, single-arm trial in Japan evaluating the safety and efficacy of cannabidiol oral solution. 27 August 2024
Pharmaceutical
Last week’s research news featured a new study from Eli Lilly, showing tirzepatide – the active ingredient of its diabetes drug Mounjaro and obesity treatment Zepbound – can delay the onset of diabetes. On the financial reporting front, Denmark’s Lundbeck released strong first-half results and raised its full year guidance. A new company – Borealis Biosciences – emerged from stealth last week, with funding from Novartis and Versant Ventures. Also of note, US biotech major Regeneron had a setback, when the Food and Drug Administration (FDA) issued a complete response letter (CRL) regarding the biologics license application (BLA) for its multiple myeloma candidate linvoseltamab. 25 August 2024
Latest In Brief for Alnylam Pharmaceuticals
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Latest Relevant Ones To Watch News
AlloVir has entered into a definitive agreement to merge with biopharma company Kalaris Therapeutics. 8 November 2024
24 October 2024
15 October 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze